MARK2 and malignant colon neoplasm: As a binding receptor of the PI3K/AKT pathway, GSK-3β exhibits serine/threonine kinase activity by phosphorylating various substrates that, in colon cancer cells, promote cell proliferation and increase gemcitabine chemoresistance [33].